The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (5 analysts) rates it none, with a mean price target of $350. Since the last review it its composite score eased.
Chesnara plc
CSN.L · LSE · GBp · Market cap $83.7B · 377 employees
Chesnara plc, together with its subsidiaries, operates in life assurance and pension businesses primarily in the United Kingdom, Sweden, and the Netherlands.
FAIL · Does not pass the screenScreen close, 2026-09-21 · not a live quote
Last reviewed 17 days ago
Screened 2026-09-21 · the tape above runs as of 17:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
What this means: price 363.00 against the desk's fair-value range, base estimate 181.50, over the last year.
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Chesnara plc holds its Markup at $363.00. Consolidating, no directional conviction, held for 335 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 335 days |
| Price at the screen | $363.00 |
| Valuation | N/A trailing · 1,383.02 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | 0.53 |
Five Screens, Shown in Full
Does not pass. Prohibited keyword in sector/industry: insurance
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Prohibited keyword in sector/industry: insurance | Fail |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | Excluded | Below 33% | Interest-bearing cash and securities are of assets, above the one-third limit. | Fail |
| Receivables | Excluded | Below 49% | Money owed to the company is of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Chesnara does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-10-08. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in GBp, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. The price runs 50.0% above the base estimate.
Third-party analyst targets: 5 covering, consensus Buy. The average target sits −1% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | 1,383.0xexpensive: the price assumes strong growth ahead |
| EPS, trailing | -0.05 |
| EPS, forward | 0.26 |
| Revenue growth | -7.7%revenue is shrinking |
| Profit margin | -3.0%currently unprofitable |
| Return on equity | -2.4%not currently earning a positive return on equity |
| FCF yield | 83.57% |
| Dividend yield | 686.00% |
| Debt to equity | 0.36minimal debt: a conservative balance sheet |
| Current ratio | 1.09adequate liquidity, worth monitoring |
| Beta | 0.53steadier than the market |
| 52-week range | 244.91 - 335.00 |
| Market cap | $83.7B |
| Employees | 377 |
The risks · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCSN.L trades on LSE (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (5 analysts) rates it none, with a mean price target of $350.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (5 analysts) rates it none, with a mean price target of $350.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (5 analysts) rates it none, with a mean price target of $350.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $314.00 | +2.7% | · | $1,027 | +2.7% |
| 2 months | $292.00 | +10.5% | · | $1,105 | +10.5% |
| 3 months | $306.35 | +5.3% | $14.80 | $1,101 | +10.1% |
| 6 months | $280.86 | +14.8% | $14.80 | $1,201 | +20.1% |
| 1 year | $255.58 | +26.2% | $22.50 | $1,350 | +35.0% |
| 2 years | $216.76 | +48.8% | $43.94 | $1,691 | +69.1% |
| 3 years | $242.13 | +33.2% | $64.76 | $1,599 | +59.9% |
| 5 years | $240.48 | +34.1% | $104.59 | $1,776 | +77.6% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CSN.L does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.